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Abstract
Background Mycobacterium malmoense is a nontubercu-
lous mycobacteria seen mainly in two age groups and with
different clinical presentations. Most patients are male
adults presenting clinical symptoms and signs similar to
those of pulmonary tuberculosis. The second group is
formed by immunocompetent children with localized
cervical lymphadenitis. Although cervical adenitis is the
main extrapulmonary manifestation of M. malmoense,
virtually all cases of cervical disease were documented in
children. Disseminated disease is rare and has been reported
in patients with severely impaired immunity.
Case report We report a case of a 47-year-old immuno-
competent man with a cervical abscess, in whom we
identified a M. malmoense pulmonary disease with multiple
cervical, thoracic and abdominal adenopathies.
Conclusion Extrapulmonary infection due to M. Mal-
moense needs to be considered on the differential diagnosis
of cervical masses and adenopathies, not only in pediatric
patients but also in adults with no impaired immunity. A
high index of suspicion for nontuberculous mycobacteria is
essential for the diagnosis and prognosis.
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Introduction
Despite being a rare pathogen, Mycobacterium malmoense
has been a subject of growing interest in recent decades,
similar to what has been happening with other emerging
nontuberculous mycobacteria (NTM).
M. malmoense is a slow-growing opportunistic and
environmental pathogen, with no person-to-person transmis-
sion reported [1]. It was first described in 1977 by Schröder
and Juhlin [2] in the city of Malmö, in Sweden, after being
isolated from respiratory tract culture samples in four patients.
Since then, an increase in the number of isolates has been
observed throughout the world, but especially in Northern
Europe [3]. This increase was due not only to an improvement
in culture methods and DNA identification techniques but it
was also consistent with a higher incidence of the NTM in
developed countries [3–7]. In Northern European countries,
M. malmoense is actually one of the most prevalent non-
tuberculous pathogens [1, 3, 6, 8, 9]. Conversely, in the
United Sates it has rarely been reported, and the majority of
the isolates do not have a clinical relevance [9, 10].
M. malmoense infections are seen mainly in two age
groups and with different clinical presentations. Most
patients are male adults, with a mean age of 60 years, with
underlying lung disease, especially chronic obstructive
pulmonary disease (COPD), and present clinical symptoms
and signs similar to those of pulmonary tuberculosis. The
second group is formed by immunocompetent children,
mostly younger than 5 years of age, with localized cervical
lymphadenitis [1, 6, 8, 11–13]. Albeit rarely, other types of
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localized disease have been described, including skin, soft
tissue infections and osteoarticular infections [14]. Dissem-
inated disease is also remarkably rare and has been reported
in patients with severely impaired immunity, except in one
immunocompetent patient, described by Sarkar et al. [15],
with pneumoconiosis and suspected of having liver and
bone marrow dissemination.
We report a case of a 47-year-old immunocompetent
man with a cervical abscess, in whom we identified a M.
malmoense pulmonary disease with multiple cervical,
thoracic and abdominal adenopathies.
Case report
A 47-year-old patient was sent to our Maxillo-Facial Surgery
Department with a soft and non-adherent supraclavicular
mass, with progressive enlargement for 2 months and without
inflammatory signs (Fig. 1). The patient also complained of
productive purulent cough for several months. There was no
weight loss, fever or asthenia.
He had a medical history of left subclavian artery
stenting in 2001, due to atherosclerotic stenosis. He smoked
one pack of cigarettes a day since adolescence and had an
alcohol consumption of 20–40 g/day. He was unemployed
and denied recent medication, travel, previous tuberculosis
or contact with a person diagnosed with tuberculosis.
Apart from the supraclavicular abscess, he had several
small palpable masses on both sides of the neck, and a poor
oral hygiene. No other signs were observed on the physical
examination.
An ultrasound and a needle aspiration were performed and
a head and neck computed tomography (CT) was requested.
On ultrasound, a 6-cm multilocular cyst was seen, as well as
multiple bilateral cervical enlarged lymph nodes.
On the following appointment, the cervical abscess had
fistulized to the skin. We analyzed the head and neck CT
that showed a hypodense lesion with 5 cm with peripheral
enhancement, multiple bilateral cervical lymphatic gangli-
ons and a pulmonary cavitation on the right apex. The
needle aspiration sample was negative for bacteria and
fungi but inconclusive for mycobacteria. Due to the high
suspicion of tuberculous infection, two ganglionar biopsies
on both sides of the neck were performed, as well as a
cutaneous excision of the fistulous tract.
The patient was then referred to the Infectious
Diseases Department for further investigation, and started
a treatment regime with isoniazid, ethambutol, rifampicin
and pyrazinamide.
His chest X-ray demonstrated extensive bilateral nodular
opacities on the apices. The high-resolution body CT
performed showed multiple cavitations on both apices (the
larger one was 6 cm), signs of acute inflammatory process
and multiple pulmonary, mediastinal and abdominal en-
larged lymph nodes (Fig. 2). The blood tests showed a C-
reactive protein value of 5.06 mg/dL (normal <0.5), but
were otherwise unremarkable, including for current HIV,
hepatitis A, B and C virus, Cytomegalovirus, Epstein–Barr
virus, Treponema pallidum, Brucella, Rickettsia conorii,
Coxiella burnetii, Toxoplasma gondii, Mycoplasma pneu-
moniae, Legionella pneumophila and Bartonella infection,
autoimmune serology, tumor markers and hormonal or
protein electrophoresis changes. His blood and urine
cultures were repeatedly negative. The tuberculin skin test
was also negative. The biopsies of the cervical lymph nodes
and the fistulized skin area showed multiple granulomatous
inflammatory processes, and all were negative for Ziehl–
Neelsen, PAS and Grocott. The direct examinations and
cultures of these samples were also unremarkable.
After 6 weeks of incubation, M. malmoense was
identified on the sputum, bronchial aspiration and bron-
Fig. 1 Cervical abscess of the patient
Fig. 2 Chest image of high-resolution computed tomography of the
patient showing multiple cavitations on both upper lobes, signs of acute
inflammatory process and distortion of the pulmonary parenchyma
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choalveolar lavage. The organism was isolated on MGIT™
liquid cultures and identified by DNA sequence analysis
with Inno-Lipa Mycobacteria v2™. No neoplastic cells
were seen on the samples. After these results, pyrazinamide
was withdrawn from the therapeutic regimen.
Two months after starting the medical treatment, a
regression of the mass and the cervical lymph nodes was
already seen as well as a remission of the purulent cough.
Currently, at the sixth month of treatment, he is on a
regimen containing isoniazid, ethambutol, rifampicin and
clarithromycin with good tolerance and clinical evolution,
and favorable prognosis.
Discussion
Pulmonary disease is the main manifestation of M.
malmoense infection in adults and usually mimics pulmo-
nary symptoms and radiological features of M. tuberculosis
pulmonary disease [1, 16]. The prevalence of pulmonary
infection is higher in patients with pre-existing pulmonary
disease, such as COPD, chronic bronchitis, emphysema,
asthma, pneumoconiosis or healed tuberculosis [1].
According to the American Thoracic Society (ATS), our
patient met the diagnostic criteria of the NTM lung disease,
which distinguishes contamination or occasional presence
of an NTM in a sample from a true pulmonary disease
(Table 1) [9].
Although it is not possible to identify any mycobacteria
from the neck samples in our patient, the histopathologic
results of the cervical biopsies, showing multiple granulo-
matous processes, and the regression of the neck tumefac-
tions after 2 months of treatment are consistent with a
disseminated M. malmoense disease in an immunocompe-
tent adult. In addition, according to the clinical investiga-
tion performed, no other current conditions responsible for
cervical adenitis were identified, such as infectious,
autoimmune, neoplastic or metabolic. Furthermore, we
believe that M. malmoense infection could be responsible
for all the other adenopathies identified on the body CT.
According to the ATS statement for NTM, even with
excised nodes showing compatible histopathology, only
50–82% will yield positive cultures, especially for fastid-
ious species [9]. As an example, a Canadian review of
NTM adenitis cases over 10 years states a positive
histopathology in 92% of the patients, but only 40% of
the cases had positive cultures in the resected nodes [17].
These results should reinforce the importance of the index
of suspicion to avoid diagnostic and treatment delays.
Upon review of the literature, cervical adenitis or abscesses
due toM. malmoense in adults have been extremely rare. Our
extensive search for similar clinical presentations on PubMed
found five cases of cervicofacial manifestations for this
pathogen in adults and, unfortunately, little was documented
about their clinical history (Table 2). Only one case, described
by Hoefsloot et al. [11], reported lymphadenitis concomitant
to a pulmonary disease, but in a patient who received
immunosupressive treatment after kidney transplantation.
Although cervical adenitis is the main extrapulmonary
manifestation ofM. malmoense, virtually all cases of cervical
adenitis were documented in children. However, this
presentation is still very uncommon when compared to the
same disease due to M. avium complex [13]. It is argued by
McCrossin and Mailman [18] that the occurrence of NTM
adenitis in young children without predisposing condi-
tions is perhaps a combination of immature immunity —
even if there is no evidence that they lack essential
Table 1 American Thoracic Society diagnostic criteria for non-
tuberculous mycobacteria lung disease
Clinical criteria
1. Pulmonary symptoms, nodular or cavitary opacities on chest
radiograph, or a high resolution CT scan that shows multifocal
bronchiectasis with multiple small nodules; and
2. Appropriate exclusion of other diagnoses
Microbiological criteria
1. Positive culture results from at least two separate expectorated
sputum samples; or
2. Positive cultures results from at least one bronchial wash or lavage; or
3. Transbronchial or other lung biopsy with mycobacterial
histopathological features (granulomatous inflammation or acid-fast
bacilli) and positive culture for NTM or biopsy showing mycobacterial
histopathological features and one or more sputum or bronchial
washings that culture positive for NTM
Table 2 Cervical isolates of Mycobacterium malmoense in adult patients described on literature
Author, year Country Patients, n Sex Age Presentation Associated pathologies
Jenkins, 1985 [4] United Kingdom 1 Female 75 Submandibular mass Not specified
Henriques, 1994 [12] Sweden 1 Female 81 Cervical abscess Anaplastic thyroid cancer
Thomsen, 2002 [14] Denmark 1 Malea 25a Cervicala Not specified
Hoefsloot, 2009 [11] Netherlands 2 Not specified Elderly Cervical lymphadenitis Not specified
a Personal communication
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immunological protection against mycobacteria as com-
pared to adults [18] — and an increased exposure of their
oral mucosa to environmental organisms due to less strict
hygienic habits and pica [17]. Having this in mind, in our
opinion, could be pertinent to consider that poor oral
hygiene may also have a similar contribution to the
etiology of the disease in adult patients. More recently, a
genetic association study, involving 81 children with NTM
cervicofacial lymphadenitis, hypothesized that children
prone to NTM bear single nucleotide polymorphisms in genes
that are relevant to mycobacteria immunity and associated
with severity of periodontal disease— +3953TT in IL1B [18].
Clinical observations also suggest that vaccination with
Bacille Calmette-Guérin (BCG) protects children against
NTM lymphadenitis, according to the rates of the disease
before and after the discontinuation of newborns’ BCG
vaccination in Sweden [12, 19]. Focal cervical NTM disease
when treated with complete surgical excision has a very high
rate of success [13, 20]. On the other hand, fine needle
aspiration biopsy or incision and drainage of the involved
lymph nodes without a complete excision may be followed
by formation of sinus with chronic drainage, as happened in
this case [9].
In contrast to localized neck NTM disease, in which a
complete surgical resection is the most effective option,
pulmonary and disseminated disease due to M. malmoense
need a long-term regimen with antimicrobials. Based on
randomized trials, the British Thoracic Society (BTS)
recommends a 12- to 24-month regimen with rifampicin
(RMP) and ethambutol (EMB) for pulmonary disease [8].
Although less tolerated and despite the lack of evidence of
benefit to date, several authors, including the ATS statement
on NTM, commented on the addition of isoniazid, cipro-
floxacin or clarithromycin to the regimen with RMP and
EMB [11, 21, 22]. Although in vitro tests suggested an
increased susceptibility for a combination with clarithromy-
cin [23] and some resistance to EMB and RMP, there is no
evidence that drug susceptibility testing contributes to the
choice and response of any treatment regimen [1, 8].
The mortality rate for M. malmoense pulmonary disease
varied among different studies conducted in Europe, and
difficulties in determining the precise cause of death may
have influenced the results. In two studies, involving 18
and 30 patients, a 13% mortality rate was noted [11, 24].
However, in a BTS trial [8] with 106 patients and, more
recently, in a study conducted by Andréjak et al. [25]
involving 46 individuals, a 5-year mortality rate of 34% and
47.2%, respectively, was observed. In two of these studies,
the outcomes have been negatively influenced by comor-
bidities, involvement of more than one lung zone, the
length of delay between the diagnosis and start of
treatment, and, less strongly, EMB resistance [8, 11].
Conclusion
Extrapulmonary infection due to M. Malmoense, besides
being a rare event, needs to be considered on the
differential diagnosis of cervical masses and adenopathies,
not only in pediatric patients but also in immunocompetent
adults. In our opinion, this case report draws further
attention to the emergence of M. malmoense as an
infectious agent, considering its pathogenicity and the
variability of clinical presentations among patients and
among different parts of the world. Further investigation is
needed to elucidate these issues.
For the diagnosis, it is essential to have a high index of
suspicion for NTM disease in order to avoid diagnostic and
treatment delays. Following appropriate laboratory procedures
and recommendations, the identification of these fastidious
agents using molecular probes is becoming more efficient.
These instruments will be a fundamental aid in decreasing
morbidity and mortality associated with the disease.
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